Long-acting cabotegravir, rilpivirine noninferior in HIV-1 - Virology Hub

Long-acting cabotegravir, rilpivirine noninferior in HIV-1



(HealthDay)—For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine.



Source link

We will be happy to hear your thoughts

Leave a reply

Virology Hub
Logo
Enable registration in settings - general
%d bloggers like this: